A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Sirukumab (Primary) ; Prednisone
  • Indications Giant cell arteritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SIRRESTA
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to discontinued, as GSK decided to return rights to sirukumab to Janssen and discontinue sirukumab development in giant cell arteritis.
    • 27 Feb 2017 Planned End Date changed from 1 Feb 2021 to 1 Nov 2020.
    • 27 Feb 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top